1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-7 of 7 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2017Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemiaSopper, S.; Mustjoki, S.; White, D.; Hughes, T.; Valent, P.; Burchert, A.; Gjertsen, B.; Gastl, G.; Baldauf, M.; Trajanoski, Z.; Giles, F.; Hochhaus, A.; Ernst, T.; Schenk, T.; Janssen, J.; Ossenkoppele, G.; Porkka, K.; Wolf, D.
2014Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibHughes, T.; Saglio, G.; Kantarjian, H.; Guilhot, F.; Niederwieser, D.; Rosti, G.; Nakaseko, C.; De Souza, C.; Kalaycio, M.; Meier, S.; Fan, X.; Menssen, H.; Larson, R.; Hochhaus, A.
2014Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyHughes, T.; Hochhaus, A.; Kantarjian, H.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; Le Coutre, P.; Rosti, G.; Ossenkoppele, G.; Lobo, C.; Shibayama, H.; Fan, X.; Menssen, H.; Kemp, C.; Larson, R.; Saglio, G.
2011Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialKantarjian, H.; Hochhaus, A.; Saglio, G.; de Souza, C.; Flinn, I.; Stenke, L.; Goh, Y.; Rosti, G.; Nakamae, H.; Gallagher, N.; Hoenekopp, A.; Blakesley, R.; Larson, R.; Hughes, T.
2010Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemiaSaglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.
2011Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid LeukemiaCortes, J.; Hochhaus, A.; Hughes, T.; Kantarjian, H.
2011BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib teatmentStein, A.; Bottino, D.; Modur, V.; Branford, S.; Kaeda, J.; Goldman, J.; Hughes, T.; Radich, J.; Hochhaus, A.

Discover